Aethlon Medical
Open
$1.94
Prev. Close
$1.94
High
$1.94
Low
$1.93
Market Snapshot
$2.54M
-0.4
-126.76
9
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The firm is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The firm is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
Recently from Cashu

Aethlon Medical Advances Final Cohort in Australian Oncology Study with Hemopurifier Treatment
Aethlon Medical, Inc. progresses significantly in its Australian oncology study, entering the third and final dosing cohort to evaluate the efficacy of its Hemopurifier treatment for cancer patients.…
Aethlon Medical's Hemopurifier Trial Shows Promising Safety and Progress in Cancer Treatment
Aethlon Medical's Hemopurifier Trial Accelerates Towards Promising Outcomes Aethlon Medical, Inc., a biotech firm specializing in innovative therapies, recently announces a significant milestone conce…
Aethlon Medical Pursues Strategic Growth Amid Clinical Advancements and Potential Partnerships
Aethlon Medical Explores Strategic Opportunities Amid Promising Clinical Developments Aethlon Medical, Inc., a San Diego-based clinical-stage medical device company, actively explores strategic opport…
Aethlon Medical Pursues Strategic Growth Through Partnerships and Clinical Innovations
Aethlon Medical's Strategic Growth: Exploring Partnerships for Future Developments Aethlon Medical, Inc., a San Diego-based clinical-stage medical device company, is taking significant steps toward it…